Friday, July 10, 2026

pharma · Weight management · Short Bowel Syndrome

Zealand Pharma

Zealand Pharma A/S is a pharma organization headquartered in EU. Primary therapeutic focus areas include Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism, Critically Ill, Mechanically Ven

Sydmarken 11, Søborg (Copenhagen), 2860, DK HQ
1998 Founded
596 Employees
EMA registrant Type
Company details
Status
Public
HQ
Sydmarken 11, Søborg (Copenhagen), 2860, DK
Founded
1998
Employees
596
Programs
18
Drugs
20
Patents
0

Quick answer

Zealand Pharma A/S is a pharma organization headquartered in EU. Primary therapeutic focus areas include Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism, Critically Ill, Mechanically Ventilated, Rhabdoid Tumor. NovaPharmaNews links 18 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (7), phase 1 (5), phase 2 (5).

Company snapshot

Zealand Pharma A/S is a [Danish](en.wikipedia.org/wiki/Denmark) [biotechnology](en.wikipedia.org/wiki/Biotechnology) research company, which designs and develops [peptide-based](en.wikipedia.org/wiki/Peptide) medicines, mainly focusing on [metabolic diseases](en.wikipedia.org/wiki/Metabolic_diseases) like [diabetes](en.wikipedia.org/wiki/Diabetes) and [obesity](en.wikipedia.org/wiki/Obesity). The

  • 18 active pipeline program(s) linked via ClinicalTrials.gov.
  • 18 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zealand Pharma. Not investment advice.

Catalysts

Upcoming readouts, regulatory dates, and congress activity.

  • approval

    Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures

Recent coverage

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Zealand Pharma.

2 active signals

24 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 7 30d
  • Nova articles 1 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Zealand Pharma.

  1. Clinical update

    ZP8396-25077 — Phase 1

  2. Clinical update

    ZP1848-23029 — Phase 3

  3. Clinical update

    ZP8396-25041 — Phase 1

  4. Clinical update

    ZP8396-24059 — Phase 1

  5. Clinical update

    ZP8396-23094 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Zealand Pharma?

    Zealand Pharma A/S is a pharma organization headquartered in EU. Primary therapeutic focus areas include Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism, Critically Ill, Mechanically Ventilated, Rhabdoid Tumor. NovaPharmaNews links 18 clinical pr

  • Is Zealand Pharma publicly traded?

    Zealand Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Zealand Pharma develop or market?

    We link 20 drug profile(s) where Zealand Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zealand-pharma-a-s#company-drugs.

  • What are the latest developments for Zealand Pharma?

    In the last 12 months our linked public records show 18 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Zealand Pharma focus on?

    Zealand Pharma focuses on Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
30
Oncology
4
Immunology
1
Infectious Disease
1